The largest community of pharma leaders

IVERIC bio Appoints Pravin U. Dugel, MD, as Executive Vice President and Chief Strategy and Business Officer

NEW YORK–()–IVERIC bio, Inc. (Nasdaq: ISEE) announced today the appointment of Pravin U. Dugel, MD, as Executive Vice President and Chief Strategy and Business Officer, effective April 1, 2020. In this role, Dr. Dugel will help shape IVERIC bio’s business development strategy going forward. Dr. Dugel brings more than 25 years’ experience in the treatment of retinal diseases. He will report to Glenn P. Sblendorio, Chief Executive Officer and President of IVERIC bio.

“We are excited to add Pravin to our management team,” stated Glenn P. Sblendorio, Chief Executive Officer and President of IVERIC bio. “In addition to being a globally recognized retinal specialist, Pravin brings an extensive network and long-standing relationships with the biotech/pharma ophthalmic industry. With IVERIC bio’s portfolio of multiple ongoing retinal disease therapeutic and gene therapy R&D programs, Pravin’s experience will be instrumental in helping us build alliances with potential future collaborators and other stakeholders. We look forward to Pravin’s input and perspective as we move the Company forward.”

“I am thrilled to join IVERIC bio,” stated Dr. Dugel. “I am particularly excited about Zimura®’s potential to positively impact and transform the lives of patients with geographic atrophy secondary to dry age-related macular degeneration who currently do not have treatment options available, as well as the potential to bring the Company’s gene therapies to patients with orphan inherited retinal diseases who also do not have treatment options available. I am eager to work with Glenn, Kourous and the experienced management team at IVERIC bio and to contribute to the Company’s strategy.”

Dr. Dugel was previously Managing Partner, Retinal Consultants of Arizona and the Retinal Research Institute; Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California; and Founding Member, Spectra Eye Institute in Sun City, Arizona. Dr. Dugel has authored more than 200 papers, 35 book chapters and has been invited to lecture at several marquis medical meetings and to serve as a visiting professor at universities worldwide, including in Japan, India, China, Malaysia, Egypt, the United Kingdom, France, Germany, Austria, Italy, Poland, Denmark, Norway, Czechoslovakia, Canada and Australia. He is on the Editorial Board of several major medical journals. Dr. Dugel is internationally recognized as a major clinical researcher and has been a principal investigator in over 100 multicenter clinical trials. His research and educational contributions earned him the prestigious Senior Honor Award from the American Academy of Ophthalmology (AAO). He has been elected and previously served as the Retina Subspecialty Day Board Chairman for the American Academy of Ophthalmology Annual Meeting, as a member of the Board of Directors of the largest retina society in the United States, the American Society of Retina Specialists (ASRS), and the largest retina society in Europe, EURETINA.

Dr. Dugel is a member of the Board of Directors and current Chair of Orbis International’s Medical Advisory Board/Medical Strategic Committee. Orbis International is a non-profit organization focused on ophthalmology training and education in the developing world. With Orbis, Dr. Dugel travels to developing countries to teach surgical techniques to local ophthalmologists and provide free surgery for those suffering from preventable blindness.

Dr. Dugel graduated summa cum laude from Columbia University in New York City. He then attended UCLA School of Medicine. He completed his residency in ophthalmology at the USC Eye Institute, Keck School of Medicine. Thereafter, he completed his medical retina fellowship at the Bascom Palmer Eye Institute and his surgical retina fellowship at the USC Eye Institute, where he was elected to serve on the faculty as the Resident Director.

About IVERIC bio
IVERIC bio is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. Vision is Our Mission. For more information on the Company please visit www.ivericbio.com.

Forward-looking Statements
Any statements in this press release about the Company’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Company’s strategy, future operations and future expectations and plans and prospects for the Company, and any other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,” “seek,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. In this press release, the Company’s forward looking statements include statements about its development strategy for Zimura, the implementation of its business plan, the timing, progress and results of clinical trials and other research and development activities, the potential utility of its product candidates, and the potential for its business development strategy. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to the initiation and the progress of research and development programs and clinical trials, availability of data from these programs, reliance on university collaborators and other third parties, establishment of manufacturing capabilities, expectations for regulatory matters, need for additional financing and negotiation and consummation of business development transactions and other factors discussed in the “Risk Factors” section contained in the quarterly and annual reports that the Company files with the Securities and Exchange Commission. Any forward-looking statements represent the Company’s views only as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. While the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law.

ISEE-G

Source

Recent Articles

Gyroscope Therapeutics Granted FDA Fast Track Designation for GT005, an Investigational Gene Therapy for Dry Age-Related Macular Degeneration

LONDON--(BUSINESS WIRE)-- #GeneTherapy--Gyroscope Therapeutics Granted FDA Fast Track Designation for GT005,...

Medeor Therapeutics’ Transplant Immune Tolerance Therapy Receives Regenerative Medicine Advanced Therapy Designation from FDA

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Medeor announces that the FDA has granted...

FDA Sued for Ignoring Petition Calling for Breast Cancer Warning Labels on Cheese

WASHINGTON--(BUSINESS WIRE)--The Physicians Committee for Responsible Medicine filed a lawsuit on...
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.